Join Transform 2021 this July 12-16. Register for the AI event of the year.


South San Francisco, Calif. biotech firm diaDexus just raised $9.2 million in sixth-round funding from Scale Venture Partners, GlaxoSithKline and Baker Brothers Advisors, according to peHUB. The company’s first and only product, the PLAC Test, is used to detect early indicators of risk for heart attack and stroke. If such conditions can be determined at an early stage, aggressive treatment can prevent possibly-fatal events from ever occurring, diaDexus claims.
Founded in 2000, the company had raised $170 million in capital previous to the recent round. This money came from Burrill & Co., Rho Ventures, Bain Capital’s Brookside Fund and Mosaix Ventures. It last raised funds at the beginning of 2007 amounting to $40 million.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member